CN116710077A - 药物制剂 - Google Patents

药物制剂 Download PDF

Info

Publication number
CN116710077A
CN116710077A CN202280010206.5A CN202280010206A CN116710077A CN 116710077 A CN116710077 A CN 116710077A CN 202280010206 A CN202280010206 A CN 202280010206A CN 116710077 A CN116710077 A CN 116710077A
Authority
CN
China
Prior art keywords
semi
compound
pharmaceutical formulation
solid
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280010206.5A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·阿默
马塞尔·德马塔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redx Pharma Ltd
Original Assignee
Redx Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Ltd filed Critical Redx Pharma Ltd
Publication of CN116710077A publication Critical patent/CN116710077A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280010206.5A 2021-01-15 2022-01-14 药物制剂 Pending CN116710077A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100526.9A GB202100526D0 (en) 2021-01-15 2021-01-15 Pharmaceutical formulation
GB2100526.9 2021-01-15
PCT/GB2022/050083 WO2022153062A1 (en) 2021-01-15 2022-01-14 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CN116710077A true CN116710077A (zh) 2023-09-05

Family

ID=74678956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280010206.5A Pending CN116710077A (zh) 2021-01-15 2022-01-14 药物制剂

Country Status (10)

Country Link
US (1) US20240082244A1 (https=)
EP (1) EP4277606A1 (https=)
JP (1) JP2024505630A (https=)
KR (1) KR20230133285A (https=)
CN (1) CN116710077A (https=)
AU (1) AU2022208241A1 (https=)
CA (1) CA3202029A1 (https=)
GB (1) GB202100526D0 (https=)
MX (1) MX2023008406A (https=)
WO (1) WO2022153062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8417154D0 (en) * 1983-07-07 1984-08-08 American Home Prod Pharmaceutical composition
WO2014186450A2 (en) * 2013-05-14 2014-11-20 The Board Of Regents Of The University Of Texas System Highly potent inhibitors of porcupine
WO2016055786A1 (en) * 2014-10-08 2016-04-14 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CN111971063A (zh) * 2018-04-06 2020-11-20 4阵营疗法公司 通过靶向调节基因信号传导网络治疗疾病

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8417154D0 (en) * 1983-07-07 1984-08-08 American Home Prod Pharmaceutical composition
WO2014186450A2 (en) * 2013-05-14 2014-11-20 The Board Of Regents Of The University Of Texas System Highly potent inhibitors of porcupine
WO2016055786A1 (en) * 2014-10-08 2016-04-14 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CN107108565A (zh) * 2014-10-08 2017-08-29 莱德克斯制药公共有限公司 作为wnt信号传送途径的抑制剂的n‑吡啶基乙酰胺衍生物
CN111971063A (zh) * 2018-04-06 2020-11-20 4阵营疗法公司 通过靶向调节基因信号传导网络治疗疾病

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OMAR FARAH ET AL.: "Regulation of porcupine-dependent Wnt signaling is essential for uterine development and function", REPRODUCTION, vol. 155, no. 1, 31 January 2018 (2018-01-31), pages 93 - 102 *
董燕: "以Wnt信号通路Porcupine蛋白为靶点的小分子抑制剂的设计、合成及活性研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 01, 15 January 2017 (2017-01-15), pages 079 - 29 *

Also Published As

Publication number Publication date
AU2022208241A9 (en) 2025-01-09
JP2024505630A (ja) 2024-02-07
GB202100526D0 (en) 2021-03-03
MX2023008406A (es) 2023-08-03
EP4277606A1 (en) 2023-11-22
AU2022208241A1 (en) 2023-07-06
US20240082244A1 (en) 2024-03-14
CA3202029A1 (en) 2022-07-21
WO2022153062A1 (en) 2022-07-21
KR20230133285A (ko) 2023-09-19

Similar Documents

Publication Publication Date Title
AU762926B2 (en) Methods and compositions for delivery of taxanes
JP2024037884A (ja) キナーゼ阻害剤の塩およびその組成物
JP4322313B2 (ja) フェノフィブレートおよびポリグリコール化グリセリドを含有する薬学的組成物
TWI233355B (en) Oral formulations for anti-tumor compounds
JP2006501134A (ja) 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物
EP2313087B2 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
HK85296A (en) Biphasic release formulations for lipophilic drugs
CN116710077A (zh) 药物制剂
TW201919626A (zh) 醫藥組合物
EP1648440B1 (en) Semi-solid formulations for the oral administration of taxoids
EP4259111B1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A CANNABINOID AGONIST
WO2004073692A1 (ja) 難水溶性薬物のハードカプセル剤
EP2036575B1 (en) Pharmaceutical compositions for oral use for treating patients affected by obesity
US20230090337A1 (en) Pharmaceutical formulations comprising 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1 -yl)-2-(1,3-dimethyl-1 hpyrazol-4-yl)-3h- imidazo[4,5-b]pyridine
Sunil et al. Development and evaluation of a chronotherapeutic drug delivery system of torsemide
US20260102403A1 (en) Oral formulations of thr-beta agonist
SU1708343A1 (ru) Способ получени твердых лекарственных форм
JP2007504190A (ja) ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−エチルプロピオネート及びそれらの塩の新規経口投与形態
HK40091367A (zh) 包含gardos通道拮抗剂的组合物及其用途
Turner Polymorphism of Polymeric Drug Excipients at High Pressure
Turner Strathclyde Institute of Pharmacy and Biomedical Science Polymorphism of Polymeric Drug Excipients at High Pressure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination